File Download
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.3389/fonc.2017.00221
- Scopus: eid_2-s2.0-85029796556
- PMID: 28993798
- WOS: WOS:000411526200001
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Challenges for Quality Assurance of Target Volume Delineation in Clinical Trials
Title | Challenges for Quality Assurance of Target Volume Delineation in Clinical Trials |
---|---|
Authors | |
Keywords | Target volume delineation variability Contouring guidelines Peer review Education program Clinical trial |
Issue Date | 2017 |
Publisher | Frontiers Research Foundation. The Journal's web site is located at http://www.frontiersin.org/oncology |
Citation | Frontiers in Oncology, 2017, v. 7, article no. 221, p. 1-8 How to Cite? |
Abstract | In recent years, new radiotherapy techniques have emerged that aim to improve treatment outcome and reduce toxicity. The standard method of evaluating such techniques is to conduct large scale multicenter clinical trials, often across continents. A major challenge for such trials is quality assurance to ensure consistency of treatment across all participating centers. Analyses from previous studies have shown that poor compliance and protocol violation have a significant adverse effect on treatment outcomes. The results of the clinical trials may, therefore, be confounded by poor quality radiotherapy. Target volume delineation (TVD) is one of the most critical steps in the radiotherapy process. Many studies have shown large inter-observer variations in contouring, both within and outside of clinical trials. High precision techniques, such as intensity-modulated radiotherapy, image-guided brachytherapy, and stereotactic radiotherapy have steep dose gradients, and errors in contouring may lead to inadequate dose to the tumor and consequently, reduce the chance of cure. Similarly, variation in organ at risk delineation will make it difficult to evaluate dose response for toxicity. This article reviews the literature on TVD variability and its impact on dosimetry and clinical outcomes. The implications for quality assurance in clinical trials are discussed. |
Persistent Identifier | http://hdl.handle.net/10722/256558 |
ISSN | 2023 Impact Factor: 3.5 2023 SCImago Journal Rankings: 1.066 |
PubMed Central ID | |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Chang, ATY | - |
dc.contributor.author | Tan, LT | - |
dc.contributor.author | Duke, S | - |
dc.contributor.author | Ng, WT | - |
dc.date.accessioned | 2018-07-20T06:36:30Z | - |
dc.date.available | 2018-07-20T06:36:30Z | - |
dc.date.issued | 2017 | - |
dc.identifier.citation | Frontiers in Oncology, 2017, v. 7, article no. 221, p. 1-8 | - |
dc.identifier.issn | 2234-943X | - |
dc.identifier.uri | http://hdl.handle.net/10722/256558 | - |
dc.description.abstract | In recent years, new radiotherapy techniques have emerged that aim to improve treatment outcome and reduce toxicity. The standard method of evaluating such techniques is to conduct large scale multicenter clinical trials, often across continents. A major challenge for such trials is quality assurance to ensure consistency of treatment across all participating centers. Analyses from previous studies have shown that poor compliance and protocol violation have a significant adverse effect on treatment outcomes. The results of the clinical trials may, therefore, be confounded by poor quality radiotherapy. Target volume delineation (TVD) is one of the most critical steps in the radiotherapy process. Many studies have shown large inter-observer variations in contouring, both within and outside of clinical trials. High precision techniques, such as intensity-modulated radiotherapy, image-guided brachytherapy, and stereotactic radiotherapy have steep dose gradients, and errors in contouring may lead to inadequate dose to the tumor and consequently, reduce the chance of cure. Similarly, variation in organ at risk delineation will make it difficult to evaluate dose response for toxicity. This article reviews the literature on TVD variability and its impact on dosimetry and clinical outcomes. The implications for quality assurance in clinical trials are discussed. | - |
dc.language | eng | - |
dc.publisher | Frontiers Research Foundation. The Journal's web site is located at http://www.frontiersin.org/oncology | - |
dc.relation.ispartof | Frontiers in Oncology | - |
dc.rights | This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. | - |
dc.subject | Target volume delineation variability | - |
dc.subject | Contouring guidelines | - |
dc.subject | Peer review | - |
dc.subject | Education program | - |
dc.subject | Clinical trial | - |
dc.title | Challenges for Quality Assurance of Target Volume Delineation in Clinical Trials | - |
dc.type | Article | - |
dc.identifier.email | Chang, ATY: atychang@hku.hk | - |
dc.identifier.email | Ng, WT: ngwt1@hkucc.hku.hk | - |
dc.identifier.authority | Chang, ATY=rp02251 | - |
dc.identifier.authority | Ng, WT=rp02671 | - |
dc.description.nature | published_or_final_version | - |
dc.identifier.doi | 10.3389/fonc.2017.00221 | - |
dc.identifier.pmid | 28993798 | - |
dc.identifier.pmcid | PMC5622143 | - |
dc.identifier.scopus | eid_2-s2.0-85029796556 | - |
dc.identifier.hkuros | 286308 | - |
dc.identifier.volume | 7 | - |
dc.identifier.spage | article no. 221, p. 1 | - |
dc.identifier.epage | article no. 221, p. 8 | - |
dc.identifier.isi | WOS:000411526200001 | - |
dc.publisher.place | Switzerland | - |
dc.identifier.issnl | 2234-943X | - |